PAP
SGMT icon

Persistent Asset Partners’s Sagimet Biosciences SGMT Stock Holding History

Persistent Asset Partners’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$80.2K Buy
+10,369
New +$70.5K 0.02% 335
2025
Q2 		– Sell
-10,597
Closed -$34.5K – 231
2025
Q1 		$34.5K Buy
+10,597
New +$44.4K 0.03% 141

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Persistent Asset Partners's SGMT Position: Q2 2026 in Review

Persistent Asset Partners opened a new position in Sagimet Biosciences (SGMT) in Q2 2026: 10,369 shares worth $80.2K. The stake represents 0.02% of the portfolio and ranks #335 among its holdings. This is a return to the name: Persistent Asset Partners previously reported a position in SGMT as recently as Q1 2025.

Persistent Asset Partners first reported a position in SGMT in Q1 2025 and has held it in 2 quarters since. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Persistent Asset Partners held 10,369 shares of Sagimet Biosciences worth $80.2K as of Q2 2026.
  • Sagimet Biosciences was a new Persistent Asset Partners position in Q2 2026.
  • Sagimet Biosciences made up 0.02% of Persistent Asset Partners's portfolio in Q2 2026, its #335 holding.
  • Persistent Asset Partners first reported a position in Sagimet Biosciences in Q1 2025 and has held it in 2 quarters since.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.